The potential reclassification of cannabinoids, particularly at the federal level, is generating considerable buzz within the industry. A shift away from Schedule I status, often viewed as outdated and hindering innovation, could unlock significant avenues for ventures. Reduced regulatory restrictions, alongside greater access to banking and fundin